文献速递新生儿儿童呼吸

低剂量与极低剂量微滴散瞳方案用于早产儿视网膜病变眼底筛查的随机对照预试验

Randomised controlled pilot trial comparing low dose and very low- dose microdrop administration of phenylephrine and cyclopentolate for retinopathy of prematurity eye examinations in neonates.
PubMed 文献 · Arch Dis Child · 2020-10-13

该前瞻性随机对照预试验纳入17例早产儿,比较苯肾上腺素1%与0.5%联合环喷托酯0.2%与0.1%微滴散瞳方案在早产儿视网膜病变眼底筛查中的效果。所有参与者瞳孔均充分散大完成检查,眼科医生对90%的检查评为容易,两组瞳孔直径无统计学差异(4.8±0.2 mm 对 5±0.2 mm,p=0.61),安全性数据组间亦无显著差异。

要点

  • 极低剂量微滴散瞳方案(苯肾上腺素0.5%+环喷托酯0.1%)可充分散大早产儿瞳孔完成ROP筛查。
  • 低剂量与极低剂量方案在瞳孔直径和筛查容易度上无显著差异。
  • 两种微滴方案的安全性数据组间无统计学显著差异。

核心结论

  • 极低剂量苯肾上腺素和环喷托酯微滴给药似乎能有效充分散大新生儿瞳孔以完成早产儿视网膜病变眼底筛查。
  • 低剂量与极低剂量微滴散瞳方案可能降低与这些药物相关的不良反应风险。

研究设计与样本

  • 纳入标准为出生体重小于1500 g或胎龄小于31周,或任何需要红光反射检查的早产儿。
  • 婴儿随机接受苯肾上腺素1%或0.5%联合环喷托酯0.2%或0.1%,双眼各1微滴。

主要发现

  • 所有参与者瞳孔均充分散大,成功完成早产儿视网膜病变眼底筛查。
  • 眼科医生对90%的检查评为容易。
  • 检查时瞳孔直径均值±标准差:治疗A组4.8±0.2 mm(95%CI 4.5至5.2),治疗B组5±0.2 mm(95%CI 4.6至5.4),p=0.61。
  • 两组安全性数据无统计学显著差异。

关键数值与推荐

  • 瞳孔充分散大的标准为大于4.1 mm。
  • 治疗A组瞳孔直径均值4.8±0.2 mm(95%CI 4.5至5.2),治疗B组5±0.2 mm(95%CI 4.6至5.4),p=0.61。
  • 眼科医生对90%的早产儿视网膜病变眼底筛查评为容易。

临床怎么用

  • 极低剂量微滴散瞳方案可用于早产儿视网膜病变眼底筛查,且可能减少药物相关不良反应。
  • 低剂量与极低剂量方案的选择需结合临床情况,因两者散瞳效果无显著差异。

局限性

  • 本研究为预试验,样本量小(17例),需更大规模研究验证。
  • 单中心研究,结果外推需谨慎。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

AIMS: To determine ifVery low dose mydriatic eye microdrop regimen sufficiently dilates the pupil (above 4.1 mm) compared with the currently used low dose mydriatic eye microdrop regimen.Cardiovascular, gastrointestinal and respiratory adverse effects occur following eye drop instillation. METHODS: Seventeen premature infants were recruited into this prospective, randomised controlled pilot trial in January 2017 to November 2018. Data were collected from the single-centre Neonatal Intensive Care Unit, Dunedin Hospital, New Zealand. The inclusion criteria were birth weight less than 1500 g or gestational age less than 31 weeks, or any premature infant requiring red reflex testing. Infants were randomised to receive either phenylephrine 1% or 0.5% and cyclopentolate 0.2% or 0.1%, 1 microdrop in both eyes. Efficacy outcome measures were pupil size at retinopathy of prematurity eye examination (ROPEE) and ophthalmologist rating of ease of screen. RESULTS: All participants had sufficient pupillary dilation for a successful ROPEE. Ophthalmologists rated the ROPEE as easy for 90% of all examinations. Pupil dilation measurements at the time of examination, mean±SD, 4.8±0.2 (95% CI 4.5 to 5.2) mm for treatment A and 5±0.2 (95%CI 4.6 to 5.4) mm for treatment B (p=0.61). There were no statistically significant differences between the groups for safety data. CONCLUSIONS: Very low dose microdrop administration of phenylephrine and cyclopentolate appears to be effective at sufficiently dilating the neonatal pupil for ROPEEs. Low dose and very low dose microdrop mydriatic regimens may also reduce the risk of unwanted adverse effects associated with these medicines. TRIAL REGISTRATION NUMBER: Australian New Zealand Clinical Trials Registry (reference ACTRN12616001266459p).

来源:Arch Dis Child,查看原文。版权归原作者所有。

引用

  1. Kremer LJ, Broadbent R, Medlicott N, et al. Randomised controlled pilot trial comparing low dose and very low- dose microdrop administration of phenylephrine and cyclopentolate for retinopathy of prematurity eye examinations in neonates. Arch Dis Child. 2020. PMID: 33051215. doi:10.1136/archdischild-2019-318733

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。